FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092243457> ?p ?o ?g. }

• W3092243457 endingPage "100826" @default.
• W3092243457 startingPage "100826" @default.
• W3092243457 abstract "Overexpression of podocalyxin (PODXL) is associated with progression, metastasis, and poor outcomes in several cancers. PODXL also plays an important role in the development of normal tissues. For antibody-based therapy to target PODXL-expressing cancers using monoclonal antibodies (mAbs), cancer-specificity is necessary to reduce the risk of adverse effects to normal tissues. In this study, we developed an anti-PODXL cancer-specific mAb (CasMab), named as PcMab-60 (IgM, kappa) by immunizing mice with soluble PODXL, which is overexpressed in LN229 glioblastoma cells. The PcMab-60 reacted with the PODXL-overexpressing LN229 (LN229/PODXL) cells and MIA PaCa-2 pancreatic cancer cells in flow cytometry but did not react with normal vascular endothelial cells (VECs), whereas one of non-CasMabs, PcMab-47 showed high reactivity for not only LN229/PODXL and MIA PaCa-2 cells but also VECs, indicating that PcMab-60 is a CasMab. Next, we engineered PcMab-60 into a mouse IgG2a-type mAb, named as 60-mG2a, to add antibody-dependent cellular cytotoxicity (ADCC). We further developed a core fucose-deficient type of 60-mG2a, named as 60-mG2a-f, to augment its ADCC activity. In vivo analysis revealed that 60-mG2a-f exerted antitumor activity in MIA PaCa-2 xenograft models at a dose of 100 μg/mouse/week administered three times. These results suggested that 60-mG2a-f could be useful for antibody-based therapy against PODXL-expressing pancreatic cancers." @default.
• W3092243457 created "2020-10-15" @default.
• W3092243457 creator A5034011259 @default.
• W3092243457 creator A5060119598 @default.
• W3092243457 creator A5060363731 @default.
• W3092243457 creator A5064054143 @default.
• W3092243457 date "2020-12-01" @default.
• W3092243457 modified "2023-10-16" @default.
• W3092243457 title "A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma" @default.
• W3092243457 cites W1477783513 @default.
• W3092243457 cites W1555499168 @default.
• W3092243457 cites W1972042205 @default.
• W3092243457 cites W2006796442 @default.
• W3092243457 cites W2030120255 @default.
• W3092243457 cites W2081867678 @default.
• W3092243457 cites W2084136419 @default.
• W3092243457 cites W2091996572 @default.
• W3092243457 cites W2098567941 @default.
• W3092243457 cites W2101120866 @default.
• W3092243457 cites W2112965812 @default.
• W3092243457 cites W2121197576 @default.
• W3092243457 cites W2132002425 @default.
• W3092243457 cites W2144746279 @default.
• W3092243457 cites W2149523673 @default.
• W3092243457 cites W2154305402 @default.
• W3092243457 cites W2155062057 @default.
• W3092243457 cites W2160936126 @default.
• W3092243457 cites W2163833204 @default.
• W3092243457 cites W2167889022 @default.
• W3092243457 cites W2268572575 @default.
• W3092243457 cites W2321741189 @default.
• W3092243457 cites W2329824702 @default.
• W3092243457 cites W2430814939 @default.
• W3092243457 cites W2566927463 @default.
• W3092243457 cites W2571830238 @default.
• W3092243457 cites W2591836828 @default.
• W3092243457 cites W2597739773 @default.
• W3092243457 cites W2607011855 @default.
• W3092243457 cites W2613226078 @default.
• W3092243457 cites W2613816154 @default.
• W3092243457 cites W2616025468 @default.
• W3092243457 cites W2728262959 @default.
• W3092243457 cites W2736282016 @default.
• W3092243457 cites W2752180315 @default.
• W3092243457 cites W2755413521 @default.
• W3092243457 cites W2756315669 @default.
• W3092243457 cites W2794649061 @default.
• W3092243457 cites W2796928365 @default.
• W3092243457 cites W2800444366 @default.
• W3092243457 cites W2898294136 @default.
• W3092243457 cites W2911299303 @default.
• W3092243457 cites W2917816084 @default.
• W3092243457 cites W2929584094 @default.
• W3092243457 cites W2932386125 @default.
• W3092243457 cites W2940509969 @default.
• W3092243457 cites W2941414834 @default.
• W3092243457 cites W2948920025 @default.
• W3092243457 cites W2960833317 @default.
• W3092243457 doi "https://doi.org/10.1016/j.bbrep.2020.100826" @default.
• W3092243457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7559861" @default.
• W3092243457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33088928" @default.
• W3092243457 hasPublicationYear "2020" @default.
• W3092243457 type Work @default.
• W3092243457 sameAs 3092243457 @default.
• W3092243457 citedByCount "18" @default.
• W3092243457 countsByYear W30922434572021 @default.
• W3092243457 countsByYear W30922434572022 @default.
• W3092243457 countsByYear W30922434572023 @default.
• W3092243457 crossrefType "journal-article" @default.
• W3092243457 hasAuthorship W3092243457A5034011259 @default.
• W3092243457 hasAuthorship W3092243457A5060119598 @default.
• W3092243457 hasAuthorship W3092243457A5060363731 @default.
• W3092243457 hasAuthorship W3092243457A5064054143 @default.
• W3092243457 hasBestOaLocation W30922434571 @default.
• W3092243457 hasConcept C121608353 @default.
• W3092243457 hasConcept C126322002 @default.
• W3092243457 hasConcept C134018914 @default.
• W3092243457 hasConcept C150903083 @default.
• W3092243457 hasConcept C153911025 @default.
• W3092243457 hasConcept C159654299 @default.
• W3092243457 hasConcept C185592680 @default.
• W3092243457 hasConcept C203014093 @default.
• W3092243457 hasConcept C207001950 @default.
• W3092243457 hasConcept C2777146197 @default.
• W3092243457 hasConcept C2779013556 @default.
• W3092243457 hasConcept C2779561371 @default.
• W3092243457 hasConcept C2780091579 @default.
• W3092243457 hasConcept C2780210213 @default.
• W3092243457 hasConcept C2781156571 @default.
• W3092243457 hasConcept C40677261 @default.
• W3092243457 hasConcept C502942594 @default.
• W3092243457 hasConcept C542903549 @default.
• W3092243457 hasConcept C553184892 @default.
• W3092243457 hasConcept C71924100 @default.
• W3092243457 hasConcept C86803240 @default.
• W3092243457 hasConcept C96232424 @default.
• W3092243457 hasConceptScore W3092243457C121608353 @default.
• W3092243457 hasConceptScore W3092243457C126322002 @default.

• next